StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Teva Pharma (TEVA) PT Lowered to $28 at Deutsche Bank
August 4, 2017 8:41 AM
Deutsche Bank lowered its price target on Teva Pharma (NYSE: TEVA) to $28.00 (from $43.00) while ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Next Articles
Teva Pharma (TEVA) Granted FDA Approval of QVAR® RediHaler (Beclomethasone Dipropionate HFA) Inhalation Aerosol
August 7, 2017 8:01 AM
Bernstein Downgrades Teva Pharma (TEVA) to Market Perform
August 4, 2017 8:02 AM
Teva Pharma (TEVA) PT Lowered to $26 at Jefferies
August 4, 2017 7:50 AM
Credit Suisse Downgrades Teva Pharma (TEVA) to Neutral
August 4, 2017 6:01 AM
RBC Capital Double Downgrades Teva Pharma (TEVA) to Underperform
August 4, 2017 5:54 AM
Cowen Downgrades Teva Pharma (TEVA) to Market Perform
August 4, 2017 5:51 AM
Teva Pharma (TEVA) PT Lowered to $23 at Piper Jaffray, Lowers EPS Estimates
August 3, 2017 2:37 PM
Teva Pharma (TEVA) PT Lowered to $27 at Cantor Fitzgerald
August 3, 2017 12:51 PM
